Infantile Spasms Therapeutics Market Report

Global Infantile Spasms Therapeutics Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 25, 2022
  • PAGES：215
  • REPORT CODE：GMM776227
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

    The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries.The classification of Infantile Spasms Therapeutics includes Oral, Injection. The proportion of Injection in 2016 is about 45%, and the proportion of Oral in 2016 is about 55%.Based on application, the nitinol medical devices market is segmented into Hospital, Clinic and others. Clinic segment accounted for larger market share in terms of sales in 2016, Clinic segmented accounted for more than 45% of the market share in 2016.United States is the largest consumption place, with a consumption market share nearly 83% in 2016. Following United States, Europe is the second largest consumption place with the consumption market share of 12.6% in 2016.The US market is dominated by two approved products H.P. Acthar Gel (adrenocorticotropin hormone) and Sabril (vigabatrin). Sabril was the first drug to be approved by the Food and Drug Administration (FDA) in 2009 and H.P. Acthar Gel (adrenocorticotropin hormone) was approved for infantile spasms in 2010. Both have Orphan Drug Exclusivity (ODE) in the US.In the future, the Infantile Spasms Therapeutics will have a good future; the price fluctuation has relationship with the raw material. The technology will more mature and the industry is more dispersion.

    Infantile Spasms Therapeutics market report explains the definition, types, applications, major countries, and major players of the Infantile Spasms Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • H Lundbeck

    • Catalyst Pharmaceuticals

    • Anavex Life Sciences

    • Orphelia Pharma

    • Retrophin

    • Valerion Therapeutics

    • Mallinckrodt

    • Insys Therapeutics

    • GW Pharmaceuticals

    By Type:

    • Oral

    • Injection

    By End-User:

    • Hospital

    • Clinic

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Infantile Spasms Therapeutics Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Infantile Spasms Therapeutics Outlook to 2028- Original Forecasts

    • 2.2 Infantile Spasms Therapeutics Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Infantile Spasms Therapeutics Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Infantile Spasms Therapeutics Market- Recent Developments

    • 6.1 Infantile Spasms Therapeutics Market News and Developments

    • 6.2 Infantile Spasms Therapeutics Market Deals Landscape

    7 Infantile Spasms Therapeutics Raw Materials and Cost Structure Analysis

    • 7.1 Infantile Spasms Therapeutics Key Raw Materials

    • 7.2 Infantile Spasms Therapeutics Price Trend of Key Raw Materials

    • 7.3 Infantile Spasms Therapeutics Key Suppliers of Raw Materials

    • 7.4 Infantile Spasms Therapeutics Market Concentration Rate of Raw Materials

    • 7.5 Infantile Spasms Therapeutics Cost Structure Analysis

      • 7.5.1 Infantile Spasms Therapeutics Raw Materials Analysis

      • 7.5.2 Infantile Spasms Therapeutics Labor Cost Analysis

      • 7.5.3 Infantile Spasms Therapeutics Manufacturing Expenses Analysis

    8 Global Infantile Spasms Therapeutics Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Infantile Spasms Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Infantile Spasms Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    9 Global Infantile Spasms Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Infantile Spasms Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Injection Consumption and Growth Rate (2017-2022)

    • 9.2 Global Infantile Spasms Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Infantile Spasms Therapeutics Market Analysis and Outlook till 2022

    • 10.1 Global Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.2.2 Canada Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.2.3 Mexico Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.2 UK Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.3 Spain Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.4 Belgium Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.5 France Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.6 Italy Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.7 Denmark Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.8 Finland Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.9 Norway Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.10 Sweden Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.11 Poland Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.12 Russia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.3.13 Turkey Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.2 Japan Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.3 India Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.4 South Korea Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.5 Pakistan Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.6 Bangladesh Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.7 Indonesia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.8 Thailand Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.9 Singapore Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.10 Malaysia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.11 Philippines Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.4.12 Vietnam Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.2 Colombia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.3 Chile Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.4 Argentina Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.5 Venezuela Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.6 Peru Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.7 Puerto Rico Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.5.8 Ecuador Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.6.2 Kuwait Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.6.3 Oman Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.6.4 Qatar Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.7.2 South Africa Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.7.3 Egypt Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.7.4 Algeria Infantile Spasms Therapeutics Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Infantile Spasms Therapeutics Consumption (2017-2022)

      • 10.8.2 New Zealand Infantile Spasms Therapeutics Consumption (2017-2022)

    11 Global Infantile Spasms Therapeutics Competitive Analysis

    • 11.1 H Lundbeck

      • 11.1.1 H Lundbeck Company Details

      • 11.1.2 H Lundbeck Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 H Lundbeck Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.1.4 H Lundbeck Infantile Spasms Therapeutics Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Catalyst Pharmaceuticals

      • 11.2.1 Catalyst Pharmaceuticals Company Details

      • 11.2.2 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.2.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Anavex Life Sciences

      • 11.3.1 Anavex Life Sciences Company Details

      • 11.3.2 Anavex Life Sciences Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Anavex Life Sciences Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.3.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Orphelia Pharma

      • 11.4.1 Orphelia Pharma Company Details

      • 11.4.2 Orphelia Pharma Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Orphelia Pharma Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Retrophin

      • 11.5.1 Retrophin Company Details

      • 11.5.2 Retrophin Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Retrophin Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.5.4 Retrophin Infantile Spasms Therapeutics Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Valerion Therapeutics

      • 11.6.1 Valerion Therapeutics Company Details

      • 11.6.2 Valerion Therapeutics Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Valerion Therapeutics Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.6.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Mallinckrodt

      • 11.7.1 Mallinckrodt Company Details

      • 11.7.2 Mallinckrodt Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Mallinckrodt Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.7.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Insys Therapeutics

      • 11.8.1 Insys Therapeutics Company Details

      • 11.8.2 Insys Therapeutics Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Insys Therapeutics Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.8.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 GW Pharmaceuticals

      • 11.9.1 GW Pharmaceuticals Company Details

      • 11.9.2 GW Pharmaceuticals Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Main Business and Markets Served

      • 11.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Infantile Spasms Therapeutics Market Outlook by Types and Applications to 2028

    • 12.1 Global Infantile Spasms Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Injection Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Infantile Spasms Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Infantile Spasms Therapeutics Market Analysis and Outlook to 2028

    • 13.1 Global Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.2.2 Canada Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.2 UK Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.3 Spain Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.5 France Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.6 Italy Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.8 Finland Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.9 Norway Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.11 Poland Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.12 Russia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.2 Japan Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.3 India Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.3 Chile Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.6 Peru Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.6.3 Oman Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Infantile Spasms Therapeutics Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Infantile Spasms Therapeutics

    • Figure of Infantile Spasms Therapeutics Picture

    • Table Global Infantile Spasms Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Infantile Spasms Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Injection Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Table North America Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure United States Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Canada Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Mexico Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure Germany Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure UK Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Spain Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Belgium Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure France Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Italy Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Denmark Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Finland Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Norway Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Sweden Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Poland Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Russia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Turkey Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table APAC Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure China Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Thailand Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Singapore Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Philippines Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table South America Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure Brazil Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Colombia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Chile Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Argentina Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Peru Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table GCC Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure Bahrain Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Oman Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Qatar Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Africa Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure Nigeria Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Africa Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Egypt Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Algeria Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Oceania Infantile Spasms Therapeutics Consumption by Country (2017-2022)

    • Figure Australia Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Infantile Spasms Therapeutics Consumption and Growth Rate (2017-2022)

    • Table H Lundbeck Company Details

    • Table H Lundbeck Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table H Lundbeck Infantile Spasms Therapeutics Main Business and Markets Served

    • Table H Lundbeck Infantile Spasms Therapeutics Product Portfolio

    • Table Catalyst Pharmaceuticals Company Details

    • Table Catalyst Pharmaceuticals Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Catalyst Pharmaceuticals Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio

    • Table Anavex Life Sciences Company Details

    • Table Anavex Life Sciences Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Anavex Life Sciences Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio

    • Table Orphelia Pharma Company Details

    • Table Orphelia Pharma Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Orphelia Pharma Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio

    • Table Retrophin Company Details

    • Table Retrophin Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Retrophin Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Retrophin Infantile Spasms Therapeutics Product Portfolio

    • Table Valerion Therapeutics Company Details

    • Table Valerion Therapeutics Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valerion Therapeutics Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio

    • Table Mallinckrodt Company Details

    • Table Mallinckrodt Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mallinckrodt Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Mallinckrodt Infantile Spasms Therapeutics Product Portfolio

    • Table Insys Therapeutics Company Details

    • Table Insys Therapeutics Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Insys Therapeutics Infantile Spasms Therapeutics Main Business and Markets Served

    • Table Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio

    • Table GW Pharmaceuticals Company Details

    • Table GW Pharmaceuticals Infantile Spasms Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GW Pharmaceuticals Infantile Spasms Therapeutics Main Business and Markets Served

    • Table GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Table North America Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Germany Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure China Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Brazil Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Infantile Spasms Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Australia Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Infantile Spasms Therapeutics Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US